• COVID-safe measures such as telehealth consults for trials, and local deliveries of trial medicines are now serving to improve clinical trial processes beyond the pandemic
• Australia’s contribution to global clinical trials continues to grow, telehealth and other digital measures offer potential to increase access via ‘teletrials’
• In 2020 Novartis contributed to 141 Australian studies, with an investment of AUD20m1
Kymriah® (tisagenlecleucel), a Chimeric antigen receptor T cell (CAR-T) one-time treatment, will be the first commercially approved CAR-T therapy to be manufactured in Australia
Providing manufacturing capabilities in Australia will help reduce transportation time previously from overseas sites, facilitating faster access to Kymriah for patient
Cell Therapies located within the Peter MacCallum Cancer Centre, Melbourne, has become the first approved local CAR-T commercial manufacturing site for Kymriah
Australia is one of seven manufacturing sites worldwide as part of the extensive Novartis CAR-T manufacturing network
With COVID-19 restrictions significantly impacting on traditional ways of working, Novartis Australia is offering associates the choice to decide how, where and when they work.
Novartis’ new flexible working model forms the basis of the organisation’s long-term vision for redefining how associates create the greatest impact in their role.
The “unbossed” future working model empowers associates to take personal responsibility to inform managers about their working schedule and align with teammates for effective collaboration.
Novartis Australia, and its generics and biosimilars division Sandoz, has confirmed that it will be working with the Australian government to provide an initial supply of generic hydroxychloroquine to support the COVID-19 pandemic response.
Novartis in Australia and New Zealand continues to closely monitor and respond to the coronavirus (COVID-19) situation. Our priority is to ensure the health and safety of our people, patients, and healthcare professionals.
Up to 8,800 hospital admissions and hundreds of deaths could be prevented, according to first Seasonal Vulnerability Report1
Thousands of older Australians are being hospitalised as temperatures plummet across Australia, with a new report revealing a 32 per cent spike in admissions during winter compared to summer for deadly and common heart conditions.1
Novartis today announced that the Therapeutic Goods Administration (TGA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10-17 years old with relapsing forms of multiple sclerosis. The registration makes Gilenya the first licenced disease-modifying treatment for children and adolescents in Australia.
